A Study About the Operation Efficacy and the Early Stage Safety of Heavy Ion Beam Treatment System in Solid Tumor

Inclusion criteria

• Must be 20 years of age inclusive, male or female
• Diagnosed with one of the following cancer: head and neck cancer, lung cancer, liver cancer, prostate cancer, osteosarcoma or bone and soft-tissue tumours
• Having a lesion of less than 12cm
• Having no metastasis at distant organ sites
• Having a life expectancy of more than 12 weeks or longer
• ECOG Performance Status (ECOG PS): 0, 1 or 2
• Maintain the function of major organs and satisfy the following criteria: WBC≥3,000 / mm3 , Plt

≥75,000 / mm3 (assuming no serious bleeding tendency below 100,000), Hb≥9.5 g / dl

• Able to maintain body position during irradiation
• Based on his/her free will, agree to participate in the clinical study and sign and date the informed consent form after understanding the clinical study.

Exclusion criteria

• Weigh more than or equal to 135kg
• Subjects need chemotherapy or immunotherapy as concomitant treatment
• Have received radiotherapy on the area planned to be irradiated
• Have received local treatment that might potentially affect endpoint evaluation, 4 weeks prior to the screening process (for instance TACE etc.)
• Have been treated with targeted therapy, chemotherapy or immunotherapy 4 weeks prior to the screening process
• Participated in other clinical studies within 12 weeks before screening (studies using questionnaire are exemption)
• Subjects contraindicated in using radiotherapy
• Wearing electronic devices, for example implantable cardiac pacemakers, implantable defibrillators, cerebrospinal stimulators, artificial hearts and cochlear implants, where the function and activity may be affected by radiation
• Have been diagnosed with another active, uncontrolled cancer
• Subjects whose irradiated area has active or persistent infectious disease
• Has autoimmune diseases or connective tissue diseases
• Subjects with other serious complications
• Pregnant or currently breastfeeding
• Planning to give birth or unable to take contraception during the screening and treatment period, as well as within 52 weeks after receiving the last treatment, regardless of gender.
• Subjects who are judged by the investigators as unsuitable